Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects
- 20 March 2000
- journal article
- review article
- Published by Elsevier in Current Opinion in Cell Biology
- Vol. 12 (2) , 166-173
- https://doi.org/10.1016/s0955-0674(99)00072-1
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Non-Ras targets of farnesyltransferase inhibitors: focus on RhoOncogene, 1998
- Gene Trapping Identifies Inhibitors of Oncogenic TransformationJournal of Biological Chemistry, 1998
- Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell linesOncogene, 1997
- The Ras-related Small GTP-binding Protein RhoB Is Immediate-early Inducible by DNA Damaging TreatmentsJournal of Biological Chemistry, 1995
- Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic miceNature Medicine, 1995
- Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.Proceedings of the National Academy of Sciences, 1994
- Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeuticCell, 1994
- Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation In Animal CellsScience, 1993
- Selective Inhibition of ras -Dependent Transformation by a Farnesyltransferase InhibitorScience, 1993
- Intracellular localization of the P21rho proteins.The Journal of cell biology, 1992